AEON (AEON Biopharma Inc.) רווח נקי למניה (EPS TTM)

Analyzing the rolling annual EPS growth chart on GURU.Markets, we see that AEON Biopharma (AEON) has stabilized this parameter at 35.30. Volatility is driven by concerns over failed drug trials and a lack of profitability. However, AEON Biopharma (AEON) is attracting top chemists through lucrative benefits packages. Prospects are bolstered by the protection of migraine treatment rights and stringent regulatory requirements for new market entrants.
AEON (AEON Bio): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The indicator is calculated as the percentage change in net income per share over the last twelve months relative to the same period last year. This metric measures the dynamics of capital generation efficiency, accounting for currency fluctuations. For AEON Biopharma (AEON), this growth reflects the monetization of highly specialized neurotoxins within medical niches. The positive trend confirms the market expansion of the drugs. By analyzing the comparable year-over-year growth of EPS TTM, an investor assesses the sustainability of the issuer's dollar margin.